C12Y 501/02
Acting on hydroxy acids and derivatives
Official title: acting on hydroxy acids and derivatives (5.1.2)
C12Y501/02 (Acting on hydroxy acids and derivatives) appears on 9 US grants and 10 published applications in this corpus.
Search patents in C12Y- Granted patents
- 9
- Published applications
- 10
- Assignees
- 4
- Inventors
- 16
- Latest grant
- 15 Nov 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2018 | 0 | 2 |
| 2019 | 1 | 5 |
| 2020 | 4 | 0 |
| 2021 | 2 | 2 |
| 2022 | 2 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
By publication year.
Subgroups
Granted patents
Recent patents
- Nucleic acid encoding hexuronate C4-epimerase variant having improved D-tagatose conversion activity, and D-tagatose production method using same15 Nov 2022US 11,499,147 B2Cj Cheiljedang Corporation
- Hexuronate C4-epimerase variant having improved D-tagatose conversion activity, and D-tagatose production method using same19 Apr 2022US 11,306,303 B2Cj Cheiljedang Corporation
- Method for producing meso-galactaric acid by contacting a fungal cell with a biomaterial having galacturonic acid20 Apr 2021US 10,982,239 B2Teknologian tutkimuskeskus VTT Oy
- Hexuronate C4-epimerase variant having improved D-tagatose conversion activity, and D-tagatose production method using same16 Mar 2021US 10,947,524 B2Cj Cheiljedang Corporation
- Hexuronate C4-epimerase variant having improved d-tagatose conversion activity, and d-tagatose production method using same13 Oct 2020US 10,801,020 B2Cj Cheiljedang Corporation
- Microorganisms converting inositol to butyrate25 Jan 2024US 2024/0026310 A1Enbiosis Biotechnology Limited
- Hexuronate c4-epimerase variant having improved d-tagatose conversion activity, and d-tagatose production method using same20 May 2021US 2021/0147824 A1Cj Cheiljedang Corporation
- Hexuronate c4-epimerase variant having improved d-tagatose conversion activity, and d-tagatose production method using same21 Jan 2021US 2021/0017559 A1Cj Cheiljedang Corporation
- Hexuronate c4-epimerase variant having improved d-tagatose conversion activity, and d-tagatose production method using same26 Dec 2019US 2019/0390188 A1Cj Cheiljedang Corporation
- Hexuronate c4-epimerase variant having improved d-tagatose conversion activity, and d-tagatose production method using same7 Nov 2019US 2019/0338329 A1Cj Cheiljedang Corporation
Most cited
By later US patents
- Hexuronate C4-epimerase mutant with improved conversion activity, and method for producing D-tagatose by using same7US 10,196,626 B2Cj Cheiljedang Corporation · 2019
- Hexuronate C4-epimerase mutant with improved conversion activity, and method for producing D-tagatose by using same4US 10,544,409 B2Cj Cheiljedang Corporation · 2020
- Hexuronate C4-epimerase variant having improved D-tagatose conversion activity, and D-tagatose production method using same2US 10,544,439 B2Cj Cheiljedang Corporation · 2020
- Hexuronate C4-epimerase variant having improved d-tagatose conversion activity, and d-tagatose production method using same1US 10,801,020 B2Cj Cheiljedang Corporation · 2020
- Hexuronate C4-epimerase variant having improved D-tagatose conversion activity, and D-tagatose production method using same1US 11,306,303 B2Cj Cheiljedang Corporation · 2022